BioNTech SE BNTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -20.71% | -1.03% | 10.05% | 11.45% | 6.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.71% | -1.03% | 10.05% | 11.45% | 6.95% |
| Cost of Revenue | 7.70% | 14.43% | 14.34% | 19.84% | 17.34% |
| Gross Profit | -26.61% | -4.95% | 8.94% | 9.41% | 5.02% |
| SG&A Expenses | 44.92% | 41.53% | 20.39% | 9.58% | -9.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -34.97% | 229.17% | 42.11% | 36.31% | 306.36% |
| Total Operating Expenses | 3.64% | 29.27% | 10.23% | 6.27% | 14.68% |
| Operating Income | -111.00% | -139.43% | -10.61% | 4.83% | -68.34% |
| Income Before Tax | -190.48% | -341.47% | -61.52% | -58.69% | -69.83% |
| Income Tax Expenses | -18.10% | 237.37% | 430.70% | 796.32% | -64.47% |
| Earnings from Continuing Operations | -171.56% | -414.65% | -78.40% | -76.39% | -26.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -171.56% | -414.65% | -78.40% | -76.39% | -26.46% |
| EBIT | -111.00% | -139.43% | -10.61% | 4.83% | -68.34% |
| EBITDA | -91.63% | -144.77% | -3.35% | 7.60% | -43.86% |
| EPS Basic | -160.09% | -393.80% | -73.39% | -75.22% | -26.18% |
| Normalized Basic EPS | -180.24% | -380.13% | -54.11% | -67.50% | -86.10% |
| EPS Diluted | -160.26% | -389.56% | -72.69% | -74.42% | -24.80% |
| Normalized Diluted EPS | -181.86% | -376.34% | -53.57% | -66.77% | -81.02% |
| Average Basic Shares Outstanding | 4.01% | 2.69% | 1.61% | 0.24% | -0.09% |
| Average Diluted Shares Outstanding | 4.36% | 2.38% | 1.29% | -0.07% | -0.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |